These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31888974)

  • 1. Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration.
    Thomas KR; Bangen KJ; Weigand AJ; Edmonds EC; Wong CG; Cooper S; Delano-Wood L; Bondi MW;
    Neurology; 2020 Jan; 94(4):e397-e406. PubMed ID: 31888974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond PD-MCI: objectively defined subtle cognitive decline predicts future cognitive and functional changes.
    Jones JD; Uribe C; Bunch J; Thomas KR
    J Neurol; 2021 Jan; 268(1):337-345. PubMed ID: 32804281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint.
    Thomas KR; Weigand AJ; Edwards LC; Edmonds EC; Bangen KJ; Ortiz G; Walker KS; Bondi MW;
    Alzheimers Res Ther; 2022 Aug; 14(1):114. PubMed ID: 35996158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain Functional Alterations and Association with Cognition in People with Preclinical Subjective Cognitive Decline and Objective Subtle Cognitive Difficulties.
    Ren S; Li J; Huang L; Huang Q; Chen K; Hu J; Jessen F; Hu X; Jiang D; Zhu L; Wang X; Guan Y; Hua F; Guo Q; Xie F
    Neuroscience; 2023 Mar; 513():137-144. PubMed ID: 36634906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional hyperperfusion in older adults with objectively-defined subtle cognitive decline.
    Thomas KR; Osuna JR; Weigand AJ; Edmonds EC; Clark AL; Holmqvist S; Cota IH; Wierenga CE; Bondi MW; Bangen KJ;
    J Cereb Blood Flow Metab; 2021 May; 41(5):1001-1012. PubMed ID: 32615887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI.
    Bangen KJ; Thomas KR; Weigand AJ; Edmonds EC; Clark AL; Solders S; Delano-Wood L; Galasko DR; Bondi MW;
    Alzheimers Dement; 2021 Oct; 17(10):1756-1762. PubMed ID: 33860596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive dispersion is a sensitive marker for early neurodegenerative changes and functional decline in nondemented older adults.
    Bangen KJ; Weigand AJ; Thomas KR; Delano-Wood L; Clark LR; Eppig J; Werhane ML; Edmonds EC; Bondi MW
    Neuropsychology; 2019 Jul; 33(5):599-608. PubMed ID: 30896235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease-related declines.
    Thomas KR; Bangen KJ; Edmonds EC; Weigand AJ; Walker KS; Bondi MW; Galasko DR;
    Alzheimers Dement (Amst); 2021; 13(1):e12238. PubMed ID: 34692978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased regional white matter hyperintensity volume in objectively-defined subtle cognitive decline and mild cognitive impairment.
    Calcetas AT; Thomas KR; Edmonds EC; Holmqvist SL; Edwards L; Bordyug M; Delano-Wood L; Brickman AM; Bondi MW; Bangen KJ; For The Alzheimer's Disease Neuroimaging Initiative
    Neurobiol Aging; 2022 Oct; 118():1-8. PubMed ID: 35809348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered functional connectivity pattern of hippocampal subfields in individuals with objectively-defined subtle cognitive decline and its association with cognition and cerebrospinal fluid biomarkers.
    Qiu T; Zeng Q; Zhang Y; Luo X; Xu X; Li X; Shen Z; Li K; Wang C; Huang P; Zhang M; Dai S; Xie F;
    Eur J Neurosci; 2022 Dec; 56(12):6227-6238. PubMed ID: 36342704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
    Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
    J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease.
    Halawa OA; Gatchel JR; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; Marshall GA;
    Alzheimers Res Ther; 2019 Jan; 11(1):14. PubMed ID: 30704519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults.
    Guo T; Landau SM; Jagust WJ;
    Neurology; 2020 Apr; 94(14):e1512-e1524. PubMed ID: 32188766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.
    Sannemann L; Bartels C; Brosseron F; Buerger K; Fliessbach K; Freiesleben SD; Frommann I; Glanz W; Heneka MT; Janowitz D; Kilimann I; Kleineidam L; Lammerding D; Laske C; Munk MHJ; Perneczky R; Peters O; Priller J; Rauchmann BS; Rostamzadeh A; Roy-Kluth N; Schild AK; Schneider A; Schneider LS; Spottke A; Spruth EJ; Teipel S; Wagner M; Wiltfang J; Wolfsgruber S; Duezel E; Jessen F;
    J Alzheimers Dis; 2024; 100(1):193-205. PubMed ID: 38848176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Amyloid-β, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals.
    Nadkarni NK; Tudorascu D; Campbell E; Snitz BE; Cohen AD; Halligan E; Mathis CA; Aizenstein HJ; Klunk WE
    J Gerontol A Biol Sci Med Sci; 2019 Oct; 74(11):1753-1760. PubMed ID: 30957843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Neuropsychological Process Scores to Identify Subtle Cognitive Decline and Predict Progression to Mild Cognitive Impairment.
    Thomas KR; Edmonds EC; Eppig J; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2018; 64(1):195-204. PubMed ID: 29865077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI.
    Lim YY; Pietrzak RH; Bourgeat P; Ames D; Ellis KA; Rembach A; Harrington K; Salvado O; Martins RN; Snyder PJ; Masters CL; Rowe CC; Villemagne VL; Maruff P
    Arch Clin Neuropsychol; 2015 Feb; 30(1):49-58. PubMed ID: 25467942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
    Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.